Wen Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wen Xiao has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Xiaoping Zhang
Department of Urology Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan China
9 shared publications Tiexi Yu
Department of Urology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China
7 shared publicationsWeiquan Li
Department of Urology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China
7 shared publicationsXiangui Meng
Department of Urology Union Hospital Tongji Medical College Huazhong University of Science and Technology Wuhan 430022 China
6 shared publications- Lei Liu
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 shared publications - Hongmei Yang
Department of Pathogen Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 shared publications
Latest Publications
- Open Access
- 9 November 2025
- Published by Wiley in Advanced Science
- Vol. 13 (5) , e08571
Thyroid Hormone Receptor β1 and PGC1α Coordinately Regulate OPA1/MFN2‐Mediated Mitochondrial Fusion and UCP1‐Mediated Lipid Browning in ccRCC
The abnormal accumulation of lipids is a hallmark of clear cell renal cell carcinoma (ccRCC). Both the thyroid hormone receptor β1 (TRβ) and peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha (PGC1α) are key regulators of mitochondrial function and lipid metabolism. However, their specific interaction and influence on ccRCC development and lipid accumulation remain poorly understood. This study identified genes jointly regulated by TRβ and PGC1α, which are implicated in lipid browning and mitochondrial fusion. Mechanistically, T3‐activated TRβ interacts with PGC1α to transcriptionally upregulate PGC1α, UCP1, and mitochondrial fusion genes OPA1 and MFN2, thereby enhancing mitochondrial activity, promoting lipid utilization, and suppressing ccRCC progression. These results indicate that the mitochondrial and metabolic effects of TRβ in ccRCC are mediated through PGC1α expression and function. Activation of the TRβ/PGC1α through hormonal and pharmacological means may offer a promising therapeutic approach for ccRCC.
- 9 November 2025
- Published by Wiley in Advanced Science
- Vol. 13 (5) , e08571
Open AccessThyroid Hormone Receptor β1 and PGC1α Coordinately Regulate OPA1/MFN2‐Mediated Mitochondrial Fusion and UCP1‐Mediated Lipid Browning in ccRCC
The abnormal accumulation of lipids is a hallmark of clear cell renal cell carcinoma (ccRCC). Both the thyroid hormone receptor β1 (TRβ) and peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha (PGC1α) are key regulators of mitochondrial function and lipid metabolism. However, their specific interaction and influence on ccRCC development and lipid accumulation remain poorly understood. This study identified genes jointly regulated by TRβ and PGC1α, which are implicated in lipid browning and mitochondrial fusion. Mechanistically, T3‐activated TRβ interacts with PGC1α to transcriptionally upregulate PGC1α, UCP1, and mitochondrial fusion genes OPA1 and MFN2, thereby enhancing mitochondrial activity, promoting lipid utilization, and suppressing ccRCC progression. These results indicate that the mitochondrial and metabolic effects of TRβ in ccRCC are mediated through PGC1α expression and function. Activation of the TRβ/PGC1α through hormonal and pharmacological means may offer a promising therapeutic approach for ccRCC.
- Open Access
- 29 October 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1487721
Causative organisms of urinary tract infections and their drug sensitivity: an analysis from various aspects
Objective: Urinary tract infection is a prevalent and complex clinical condition. To treat urinary tract infections more effectively, we sought to describe the distribution and antibiotic susceptibility of causative organisms in patients. Materials and methods: We retrospectively analyzed 3,685 patients with urinary tract infections between 2022 and 2023, treated at the Department of Urology of Wuhan Union Hospital. Clinical data, urine culture results, and drug sensitivity test data were collected for further analysis. Results: Of all 3,685 patients with positive urine cultures, 3,899 strains of causative organisms were isolated. Gram-negative bacteria (2,242/3899, 57.50%) were the most common causative organisms, among which Escherichia coli (1,250/3899, 32.06%) was the most common species. Drug sensitivity tests showed that most pathogens exhibited high sensitivity to restricted antibiotics (e.g., carbapenems) and cephalosporins (nearly 100 and 90%, respectively), but high resistance rates to quinolones and macrolides (over 50%). Comparing the distribution of causative organisms and drug sensitivity between 2022 and 2023, we found that the proportion of E. coli and Proteus mirabilis have increased significantly ( p = 0.0066 and p = 0.0003, respectively), while the proportion of Enterococcus faecium have decreased significantly ( p = 0.0419). Compared to non-stone infections, stone-associated infections showed a significantly higher proportion of P. mirabilis ( p < 0.0001), consistent with its role in magnesium ammonium phosphate stones formation. Significant differences in pathogen distribution were also observed between outpatient and ward settings ( E. coli , Enterococcus faecalis , Klebsiella pneumoniae , Staphylococcus epidermidis , Enterobacter aerogenes , E. faecium , Pseudomonas aeruginosa , and Acinetobacter baumannii ). Conclusion: Based on the above results, cephalosporins are recommended to be applied in the initial empirical treatment, with timely adjustment according to the results of antimicrobial susceptibility testing.
- 29 October 2025
- Published by Frontiers Media SA in Frontiers in Public Health
- Vol. 13, 1487721
Open AccessCausative organisms of urinary tract infections and their drug sensitivity: an analysis from various aspects
Objective: Urinary tract infection is a prevalent and complex clinical condition. To treat urinary tract infections more effectively, we sought to describe the distribution and antibiotic susceptibility of causative organisms in patients. Materials and methods: We retrospectively analyzed 3,685 patients with urinary tract infections between 2022 and 2023, treated at the Department of Urology of Wuhan Union Hospital. Clinical data, urine culture results, and drug sensitivity test data were collected for further analysis. Results: Of all 3,685 patients with positive urine cultures, 3,899 strains of causative organisms were isolated. Gram-negative bacteria (2,242/3899, 57.50%) were the most common causative organisms, among which Escherichia coli (1,250/3899, 32.06%) was the most common species. Drug sensitivity tests showed that most pathogens exhibited high sensitivity to restricted antibiotics (e.g., carbapenems) and cephalosporins (nearly 100 and 90%, respectively), but high resistance rates to quinolones and macrolides (over 50%). Comparing the distribution of causative organisms and drug sensitivity between 2022 and 2023, we found that the proportion of E. coli and Proteus mirabilis have increased significantly ( p = 0.0066 and p = 0.0003, respectively), while the proportion of Enterococcus faecium have decreased significantly ( p = 0.0419). Compared to non-stone infections, stone-associated infections showed a significantly higher proportion of P. mirabilis ( p < 0.0001), consistent with its role in magnesium ammonium phosphate stones formation. Significant differences in pathogen distribution were also observed between outpatient and ward settings ( E. coli , Enterococcus faecalis , Klebsiella pneumoniae , Staphylococcus epidermidis , Enterobacter aerogenes , E. faecium , Pseudomonas aeruginosa , and Acinetobacter baumannii ). Conclusion: Based on the above results, cephalosporins are recommended to be applied in the initial empirical treatment, with timely adjustment according to the results of antimicrobial susceptibility testing.
- Open Access
- 22 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (20)
SPOP mediates apoptosis and protects against necroptosis by regulating ubiquitination of RIPK1 and RIPK3
Apoptosis and necroptosis are 2 distinct destinies of cells stimulated with TNF-α; however, it remains unclear how apoptosis and necroptosis are differentially regulated. This study validates the key regulatory role of speckle-type POZ protein (SPOP) in balancing apoptosis and necroptosis. SPOP promotes the polyubiquitination and degradation of receptor-interacting serine/threonine-protein kinase 3 (RIPK3), thereby inhibiting necrosome formation and decreasing cellular sensitivity to necroptosis. Conversely, SPOP interacted with RIPK1 independently of its E3 ubiquitin ligase activity, protecting it from ubiquitination and degradation, thereby enhancing RIPK1 expression and cellular sensitivity to apoptosis. Inhibiting RIPK1 kinase activity with 7-Cl-O-Nec-1 impeded both SPOP-mediated apoptosis and SPOP deficiency–mediated necroptosis. Besides, inhibition or loss of RIPK3 rescued SPOP deficiency–mediated necroptosis. Pancancer analyses indicated that the SPOP/RIPK1/RIPK3 axis is dysfunctional in a variety of tumors. In 3 representative tumor types with high expression of SPOP and RIPK1, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, and breast invasive carcinoma, this regulatory mechanism remains applicable. Based on these findings, a combination therapy using the second mitochondria-derived activator of caspases (Smac) mimetic SM164 and sunitinib was developed, demonstrating a more pronounced efficacy than sunitinib monotherapy, and this sensitizing effect was dependent on the expression level of RIPK1. These results suggest that the combination of Smac mimetics with tyrosine kinase inhibitors holds potential clinical value for tumors with dysregulated SPOP/RIPK1/RIPK3 signaling.
- 22 October 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (20)
Open AccessSPOP mediates apoptosis and protects against necroptosis by regulating ubiquitination of RIPK1 and RIPK3
Apoptosis and necroptosis are 2 distinct destinies of cells stimulated with TNF-α; however, it remains unclear how apoptosis and necroptosis are differentially regulated. This study validates the key regulatory role of speckle-type POZ protein (SPOP) in balancing apoptosis and necroptosis. SPOP promotes the polyubiquitination and degradation of receptor-interacting serine/threonine-protein kinase 3 (RIPK3), thereby inhibiting necrosome formation and decreasing cellular sensitivity to necroptosis. Conversely, SPOP interacted with RIPK1 independently of its E3 ubiquitin ligase activity, protecting it from ubiquitination and degradation, thereby enhancing RIPK1 expression and cellular sensitivity to apoptosis. Inhibiting RIPK1 kinase activity with 7-Cl-O-Nec-1 impeded both SPOP-mediated apoptosis and SPOP deficiency–mediated necroptosis. Besides, inhibition or loss of RIPK3 rescued SPOP deficiency–mediated necroptosis. Pancancer analyses indicated that the SPOP/RIPK1/RIPK3 axis is dysfunctional in a variety of tumors. In 3 representative tumor types with high expression of SPOP and RIPK1, kidney renal clear cell carcinoma, liver hepatocellular carcinoma, and breast invasive carcinoma, this regulatory mechanism remains applicable. Based on these findings, a combination therapy using the second mitochondria-derived activator of caspases (Smac) mimetic SM164 and sunitinib was developed, demonstrating a more pronounced efficacy than sunitinib monotherapy, and this sensitizing effect was dependent on the expression level of RIPK1. These results suggest that the combination of Smac mimetics with tyrosine kinase inhibitors holds potential clinical value for tumors with dysregulated SPOP/RIPK1/RIPK3 signaling.
- Open Access
- 22 August 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (12) , 5361-5377
E3 ligase MKRN2 destabilizes PPP2CA proteins to inactivate canonical Wnt pathway and mitigates tumorigenesis of clear cell renal cell carcinoma
Background: Emerging evidence suggests that Makorin Ring Finger Proteins (MKRNs) are dysregulated in various human malignancies. However, the clinical and biological significance of MKRN2 in clear cell renal cell carcinoma (ccRCC) has been minimally explored. In this study, we investigated the exceptional role of MKRN2 in ccRCC.
- 22 August 2025
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 21 (12) , 5361-5377
Open AccessE3 ligase MKRN2 destabilizes PPP2CA proteins to inactivate canonical Wnt pathway and mitigates tumorigenesis of clear cell renal cell carcinoma
Background: Emerging evidence suggests that Makorin Ring Finger Proteins (MKRNs) are dysregulated in various human malignancies. However, the clinical and biological significance of MKRN2 in clear cell renal cell carcinoma (ccRCC) has been minimally explored. In this study, we investigated the exceptional role of MKRN2 in ccRCC.
- Open Access
- 19 July 2025
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 22 (13) , 3354-3370
CLCN5 inhibits tumorigenesis and fatty acid accumulation in clear cell renal cell carcinoma by regulating Enoyl CoA hydratase and 3-Hydroxyacyl CoA dehydrogenase
Clear cell renal cell carcinoma (ccRCC), a globally prevalent and highly aggressive malignancy, is characterized by abnormal lipid accumulation and high morbidity. However, the complex pathological mechanisms underlying its development remain largely unexplored, necessitating further research efforts. In this study, we employed Weighted Gene Co-expression Network Analysis (WGCNA) and identified Chloride Voltage-Gated Channel 5 (CLCN5), a member of the CIC family, as a potential hub gene involved in fatty acid degradation. Our findings suggest that downregulated CLCN5 was negatively correlated with the malignant characteristics and prognosis of ccRCC. In vitro experiments demonstrated that CLCN5 overexpression significantly impacts fatty acid oxidation and inhibits tumor proliferation, metastasis, migration, and invasion in ccRCC. Mechanistically, CLCN5 restrains the proliferation and migration of ccRCC cells by decreasing lipid accumulation through the effects of Enoyl CoA hydratase and 3-Hydroxyacyl CoA dehydrogenase (EHHADH). Collectively, these findings suggest that CLCN5/EHHADH-mediated fatty acid metabolism could be a potential strategy for ccRCC treatment.
- 19 July 2025
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 22 (13) , 3354-3370
Open AccessCLCN5 inhibits tumorigenesis and fatty acid accumulation in clear cell renal cell carcinoma by regulating Enoyl CoA hydratase and 3-Hydroxyacyl CoA dehydrogenase
Clear cell renal cell carcinoma (ccRCC), a globally prevalent and highly aggressive malignancy, is characterized by abnormal lipid accumulation and high morbidity. However, the complex pathological mechanisms underlying its development remain largely unexplored, necessitating further research efforts. In this study, we employed Weighted Gene Co-expression Network Analysis (WGCNA) and identified Chloride Voltage-Gated Channel 5 (CLCN5), a member of the CIC family, as a potential hub gene involved in fatty acid degradation. Our findings suggest that downregulated CLCN5 was negatively correlated with the malignant characteristics and prognosis of ccRCC. In vitro experiments demonstrated that CLCN5 overexpression significantly impacts fatty acid oxidation and inhibits tumor proliferation, metastasis, migration, and invasion in ccRCC. Mechanistically, CLCN5 restrains the proliferation and migration of ccRCC cells by decreasing lipid accumulation through the effects of Enoyl CoA hydratase and 3-Hydroxyacyl CoA dehydrogenase (EHHADH). Collectively, these findings suggest that CLCN5/EHHADH-mediated fatty acid metabolism could be a potential strategy for ccRCC treatment.
- Open Access
- 20 February 2025
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1532491
NK cells in renal cell carcinoma and its implications for CAR-NK therapy
Renal cell carcinoma (RCC) is a malignancy that makes up 3% of adult cancers and 20%–30% of patients were diagnosed with metastatic RCC in the beginning, while the median overall survival (OS) of metastatic RCC systemic therapy ranges from 16 months to 50 months. Immunotherapy, a novel therapy that relies on the specific binding of immune cells and tumor cells, may be a potential therapy for advanced renal cell carcinoma. While chimeric antigen receptor NK-cell (CAR-NK) therapy has been investigated in a variety of solid tumors, specific research on its application to RCC has also been reported by several teams. In this review, we introduced the cytotoxicity mechanisms of NK cells, summarized the connections between RCC and NK cells, and posted new insights into renal cell carcinoma CAR-NK therapy. To date, most researches focusing on renal cell carcinoma and NK cells only claimed the mechanisms of NK cell cytotoxicity and NK cell immune suppression and even immune escape, yet the molecules involved could also be interesting targets for renal cell carcinoma CAR-NK therapy.
- 20 February 2025
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 13, 1532491
Open AccessNK cells in renal cell carcinoma and its implications for CAR-NK therapy
Renal cell carcinoma (RCC) is a malignancy that makes up 3% of adult cancers and 20%–30% of patients were diagnosed with metastatic RCC in the beginning, while the median overall survival (OS) of metastatic RCC systemic therapy ranges from 16 months to 50 months. Immunotherapy, a novel therapy that relies on the specific binding of immune cells and tumor cells, may be a potential therapy for advanced renal cell carcinoma. While chimeric antigen receptor NK-cell (CAR-NK) therapy has been investigated in a variety of solid tumors, specific research on its application to RCC has also been reported by several teams. In this review, we introduced the cytotoxicity mechanisms of NK cells, summarized the connections between RCC and NK cells, and posted new insights into renal cell carcinoma CAR-NK therapy. To date, most researches focusing on renal cell carcinoma and NK cells only claimed the mechanisms of NK cell cytotoxicity and NK cell immune suppression and even immune escape, yet the molecules involved could also be interesting targets for renal cell carcinoma CAR-NK therapy.
- 14 July 2024
- Published by Elsevier in Cancer Letters
- Vol. 598, 217118
ZDHHC9-mediated Bip/GRP78 S-palmitoylation inhibits unfolded protein response and promotes bladder cancer progression
- 14 July 2024
- Published by Elsevier in Cancer Letters
- Vol. 598, 217118
ZDHHC9-mediated Bip/GRP78 S-palmitoylation inhibits unfolded protein response and promotes bladder cancer progression
- Open Access
- 14 November 2023
- Published by Springer Nature in Molecular Biomedicine
- Vol. 4 (1) , 1-13
Downregulation of RNA binding protein 47 predicts low survival in patients and promotes the development of renal cell malignancies through RNA stability modification
RNA binding proteins (RBPs) are crucial for cell function, tissue growth, and disease development in disease or normal physiological processes. RNA binding motif protein 47 (RBM47) has been proven to have anti-tumor effects on many cancers, but its effect is not yet clear in renal cancer. Here, we demonstrated the expression and the prognostic role of RBM47 in public databases and clinical samples of clear cell renal carcinoma (ccRCC) with bioinformatics analysis. The possible mechanism of RBM47 in renal cancer was verified by gene function prediction and in vitro experiments. The results showed that RBM47 was downregulated in renal cancers when compared with control groups. Low RBM47 expression indicated poor prognosis in ccRCC. RBM47 expression in renal cancer cell lines was reduced significantly when compared to normal renal tubular epithelial cells. Epithelial-mesenchymal transition (EMT) and transforming growth factor-β signaling pathway was associated with RBM47 in ccRCC by Gene set enrichment analysis. RBM47 expression had a positive correlation with e-cadherin, but a negative correlation with snail and vimentin. RBM47 overexpression could repress the migration, invasion activity, and proliferation capacity of renal cancer cells, while RBM47 inhibition could promote the development of the malignant features through EMT signaling by RNA stability modification. Therefore, our results suggest that RBM47, as a new molecular biomarker, may play a key role in the cancer development of ccRCC.
- 14 November 2023
- Published by Springer Nature in Molecular Biomedicine
- Vol. 4 (1) , 1-13
Open AccessDownregulation of RNA binding protein 47 predicts low survival in patients and promotes the development of renal cell malignancies through RNA stability modification
RNA binding proteins (RBPs) are crucial for cell function, tissue growth, and disease development in disease or normal physiological processes. RNA binding motif protein 47 (RBM47) has been proven to have anti-tumor effects on many cancers, but its effect is not yet clear in renal cancer. Here, we demonstrated the expression and the prognostic role of RBM47 in public databases and clinical samples of clear cell renal carcinoma (ccRCC) with bioinformatics analysis. The possible mechanism of RBM47 in renal cancer was verified by gene function prediction and in vitro experiments. The results showed that RBM47 was downregulated in renal cancers when compared with control groups. Low RBM47 expression indicated poor prognosis in ccRCC. RBM47 expression in renal cancer cell lines was reduced significantly when compared to normal renal tubular epithelial cells. Epithelial-mesenchymal transition (EMT) and transforming growth factor-β signaling pathway was associated with RBM47 in ccRCC by Gene set enrichment analysis. RBM47 expression had a positive correlation with e-cadherin, but a negative correlation with snail and vimentin. RBM47 overexpression could repress the migration, invasion activity, and proliferation capacity of renal cancer cells, while RBM47 inhibition could promote the development of the malignant features through EMT signaling by RNA stability modification. Therefore, our results suggest that RBM47, as a new molecular biomarker, may play a key role in the cancer development of ccRCC.
- Open Access
- 14 September 2023
- Published by Wiley in MedComm – Oncology
- Vol. 2 (3)
Gene LY96 is an M2 macrophage‐related biomarker and is associated with immunosuppression in renal cell carcinoma
Lymphocyte Antigen 96 (LY96) was identified as an oncogene in several tumors. However, its role in renal cancer has not been explored. In the study, LY96 is identified abnormally expressed using several public kidney cancer sequencing data. The expression level of LY96 is validated using paired clinical samples. Survival analyses and ROC curves are used to examine its prognostic and diagnostic value. Gene sets enrichment analyses (GSEA) show LY96 might influence immune processes. Then immune infiltration analyses results suggest that LY96 is positively correlated with M2 macrophages infiltration in RCC. Single‐cell data are used to verify its association with macrophages. Moreover, LY96 is positively with various immune scores and might affect the efficacy of immunotherapy. Drug screening results show LY96 might be the target of vemurafenib and etoposide. Further experiments confirm the spatial co‐localization of LY96 and M2, and knocking down LY96 can inhibit M2 polarization. Cell viability experiments indicate that knocking down LY96 would result in a decrease in the resistance of M2 macrophages to etoposide. The study shows LY96 could act as an unfavorable biomarker for RCC and possibly contribute to cancer progression by promoting the infiltration of M2 macrophage. LY96 could be a novel therapeutic target for RCC.
- 14 September 2023
- Published by Wiley in MedComm – Oncology
- Vol. 2 (3)
Open AccessGene LY96 is an M2 macrophage‐related biomarker and is associated with immunosuppression in renal cell carcinoma
Lymphocyte Antigen 96 (LY96) was identified as an oncogene in several tumors. However, its role in renal cancer has not been explored. In the study, LY96 is identified abnormally expressed using several public kidney cancer sequencing data. The expression level of LY96 is validated using paired clinical samples. Survival analyses and ROC curves are used to examine its prognostic and diagnostic value. Gene sets enrichment analyses (GSEA) show LY96 might influence immune processes. Then immune infiltration analyses results suggest that LY96 is positively correlated with M2 macrophages infiltration in RCC. Single‐cell data are used to verify its association with macrophages. Moreover, LY96 is positively with various immune scores and might affect the efficacy of immunotherapy. Drug screening results show LY96 might be the target of vemurafenib and etoposide. Further experiments confirm the spatial co‐localization of LY96 and M2, and knocking down LY96 can inhibit M2 polarization. Cell viability experiments indicate that knocking down LY96 would result in a decrease in the resistance of M2 macrophages to etoposide. The study shows LY96 could act as an unfavorable biomarker for RCC and possibly contribute to cancer progression by promoting the infiltration of M2 macrophage. LY96 could be a novel therapeutic target for RCC.